<DOC>
	<DOCNO>NCT01467947</DOCNO>
	<brief_summary>This prospective , international , multi-center , non-randomized , single arm , open-label , postmarketing study investigate formation inhibitory anti-C1-INH antibody HAE subject treat intravenously Berinert . Individual treatment duration per subject 9 month , irrespective number treat attack . All subject receive 20 IU Berinert/kg body weight per attack .</brief_summary>
	<brief_title>Postmarketing Immunogenicity Study HAE Subjects Treated With Berinert</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>Diagnosis congenital C1INH deficiency ( HAE type I II ) assess investigator likely require intravenous ( IV ) Berinert treatment study period . Male female , â‰¥ 12 year age time sign informed consent . Written inform consent study participation obtain undergo study specific procedure . Incurable malignancy last 6 month prior study entry . Acquired angioedema due C1INH deficiency . All type angioedema associate C1INH deficiency . Use C1INH product Berinert within 30 day study , plan use study . Immunization within 30 day prior study entry . Autoimmune condition require use immunosuppressant study . Known suspect hypersensitivity C1INH . Participation previous Berinert study antiC1INH antibody result submit Food Drug Administration .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>